Editing IL6 in Liver cirrhosis

 '''Key issues concerning the case'''

{{tp|p=7513204|t=1994. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice.|pdf=|usr=}}{{7513204}}
{{tp|p=2505958|t=1989. High interleukin-6 serum levels and increased production by leucocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines production.|pdf=|usr=}}{{2505958}}
{{tp|p=10613740|t=2000. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice.|pdf=|usr=}}{{10613740}}
{{tp|p=10534116|t=1999. Attenuated liver fibrosis and depressed serum albumin levels in carbon tetrachloride-treated IL-6-deficient mice.|pdf=|usr=}}{{10534116}}
{{tp|p=8972745|t=1996. Anti-interleukin-6 autoantibodies in plasma are associated with an increased frequency of infections and increased mortality of patients with alcoholic cirrhosis.|pdf=|usr=}}{{8972745}}
{{tp|p=1397888|t=1992. Immunoglobulin A and interleukin 6 form a positive secretory feedback loop: a study of normal subjects and alcoholic cirrhotics.|pdf=|usr=}}{{1397888}}

 '''Cirrhosis makes IL6'''

{{tp|p=26855498|t=2016. Carbohydrate Deficient Transferrin and Interleukin-6 as Predictors of Fibrosis in Alcohol Cirrhosis.|pdf=|usr=}}{{26855498}}
{{tp|p=26807383|t=2015. IL-6 Plays a Crucial Role in HBV Infection.|pdf=|usr=}}{{26807383}}
{{tp|p=26573228|t=2015. LPS-induced TNF-alpha factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.|pdf=|usr=}}{{26573228}}
{{tp|p=26448742|t=2015. Proinflammatory Cytokines (IL-1alpha, IL-6) and Hepatocyte Growth Factor in Patients with Alcoholic Liver Cirrhosis.|pdf=|usr=}}{{26448742}}
{{tp|p=26090463|t=2015. Liver Failure Impairs the Intrahepatic Elimination of Interleukin-6, Tumor Necrosis Factor-Alpha, Hepatocyte Growth Factor, and Transforming Growth Factor-Beta.|pdf=|usr=}}{{26090463}}
{{tp|p=26039496|t=2015. Detecting minimal hepatic encephalopathy in an endemic country for hepatitis B: the role of psychometrics and serum IL-6.|pdf=|usr=}}{{26039496}}
{{tp|p=25899133|t=2017. IL-6 significantly correlates with p-STAT3 expression and presents high variceal bleeding with mortality in cirrhotic patients: A cross-sectional study.|pdf=|usr=}}{{25899133}}
{{tp|p=25870985|t=2015. Association of HIV, hepatitis C virus and liver fibrosis severity with interleukin-6 and C-reactive protein levels.|pdf=|usr=}}{{25870985}}
{{tp|p=25421508|t=2014. Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines.|pdf=|usr=}}{{25421508}}
{{tp|p=25214799|t=2014. Interleukins in chronic liver disease: lessons learned from experimental mouse models.|pdf=|usr=}}{{25214799}}
{{tp|p=24849676|t=2014. Purinergic signaling via P2Y receptors up-mediates IL-6 production by liver macrophages/Kupffer cells.|pdf=|usr=}}{{24849676}}
{{tp|p=23928410|t=2013. Uncovering the molecular events associated with increased intestinal permeability in liver cirrhosis: the pivotal role of enterocyte tight junctions and future perspectives.|pdf=|usr=}}{{23928410}}
{{tp|p=23813132|t=2013. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.|pdf=|usr=}}{{23813132}}
{{tp|p=23515243|t=2012. Tumor necrosis factor-alpha and interleukin-6 in cirrhotic patients with spontaneous bacterial peritonitis.|pdf=|usr=}}{{23515243}}
{{tp|p=23150092|t=2013. Hepatitis C virus promotes T-helper (Th)17 responses through thymic stromal lymphopoietin production by infected hepatocytes.|pdf=|usr=}}{{23150092}}
{{tp|p=23144154|t=2012. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.|pdf=|usr=}}{{23144154}}
{{tp|p=22851861|t=2012. Lentiviral vector-mediated down-regulation of IL-17A receptor in hepatic stellate cells results in decreased secretion of IL-6.|pdf=|usr=}}{{22851861}}
{{tp|p=22687286|t=2012. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice.|pdf=|usr=}}{{22687286}}
{{tp|p=22507133|t=2012. Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate.|pdf=|usr=}}{{22507133}}
{{tp|p=21622209|t=2011. JAK-STAT signaling in hepatic fibrosis.|pdf=|usr=}}{{21622209}}
{{tp|p=19950277|t=2009. Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia.|pdf=|usr=}}{{19950277}}
{{tp|p=19855130|t=2009. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha.|pdf=|usr=}}{{19855130}}
{{tp|p=19652645|t=2009. Cholestasis downregulate hepcidin expression through inhibiting IL-6-induced phosphorylation of signal transducer and activator of transcription 3 signaling.|pdf=|usr=}}{{19652645}}
{{tp|p=19604266|t=2009. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis.|pdf=|usr=}}{{19604266}}
{{tp|p=19438606|t=2009. An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease.|pdf=|usr=}}{{19438606}}
{{tp|p=19032584|t=2009. Molecular mechanisms of alcoholic fatty liver.|pdf=|usr=}}{{19032584}}
{{tp|p=17962206|t=2008. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma.|pdf=|usr=}}{{17962206}}
{{tp|p=16688802|t=2006. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.|pdf=|usr=}}{{16688802}}
{{tp|p=16266225|t=2005. IL-6 and extracellular matrix remodeling.|pdf=|usr=}}{{16266225}}
{{tp|p=15860640|t=2005. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells.|pdf=|usr=}}{{15860640}}
{{tp|p=15763341|t=2005. Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression.|pdf=|usr=}}{{15763341}}
{{tp|p=12547716|t=2003. Expression and DNA-binding activity of signal transducer and activator of transcription 3 in alcoholic cirrhosis compared to normal liver and primary biliary cirrhosis in humans.|pdf=|usr=}}{{12547716}}
{{tp|p=12077104|t=2002. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6.|pdf=|usr=}}{{12077104}}
{{tp|p=11337499|t=2001. JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells.|pdf=|usr=}}{{11337499}}
{{tp|p=10793074|t=2000. The development and compensation of biliary cirrhosis in interleukin-6-deficient mice.|pdf=|usr=}}{{10793074}}
{{tp|p=9524291|t=1998. Flow cytometric analysis of IL-6 receptors on peripheral lymphocytes in patients with primary biliary cirrhosis.|pdf=|usr=}}{{9524291}}
{{tp|p=9524290|t=1998. Analysis of serum cytokine levels in primary biliary cirrhosis patients and healthy adults.|pdf=|usr=}}{{9524290}}
{{tp|p=8586322|t=1995. Increased concentrations of tumor necrosis factor and interleukin-6 contribute to the hemostatic abnormalities in advanced liver disease.|pdf=|usr=}}{{8586322}}
{{tp|p=8137551|t=1994. IL-6 induces hepatic inflammation and collagen synthesis in vivo.|pdf=|usr=}}{{8137551}}
{{tp|p=8137550|t=1994. Induction of autoimmune disease by graft-versus-host reaction across MHC class II difference: modification of the lesions in IL-6 transgenic mice.|pdf=|usr=}}{{8137550}}
{{tp|p=1597519|t=1992. Localisation of intrahepatic interleukin 6 in patients with acute and chronic liver disease.|pdf=|usr=}}{{1597519}}
{{tp|p=2044224|t=1991. Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis.|pdf=|usr=}}{{2044224}}
{{tp|p=23262249|t=2013. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.|pdf=|usr=}}{{23262249}}
{{tp|p=23084463|t=2013. Correlation between interleukin-6 and ammonia in patients with overt hepatic encephalopathy due to cirrhosis.|pdf=|usr=}}{{23084463}}
{{tp|p=22883217|t=2012. Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy.|pdf=|usr=}}{{22883217}}
{{tp|p=22710653|t=2012. Laparoscopic and open splenectomy for splenomegaly secondary to liver cirrhosis: an evaluation of immunity.|pdf=|usr=}}{{22710653}}
{{tp|p=22646055|t=2012. Relationship between interleukin-6 and ammonia in patients with minimal hepatic encephalopathy due to liver cirrhosis.|pdf=|usr=}}{{22646055}}
{{tp|p=22634708|t=2012. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases.|pdf=|usr=}}{{22634708}}
{{tp|p=22510812|t=2012. TH-1 and TH-2 cytokines in stable chronic alcoholics.|pdf=|usr=}}{{22510812}}
{{tp|p=22367091|t=2012. Cytokines in alcoholic liver disease.|pdf=|usr=}}{{22367091}}
{{tp|p=22230324|t=2012. Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naive hepatitis B infection patients.|pdf=|usr=}}{{22230324}}
{{tp|p=21830421|t=2011. The relation between pathogenesis of liver cirrhosis, hepatic encephalopathy and serum cytokine levels: what is the role of tumor necrosis factor alpha?|pdf=|usr=}}{{21830421}}
{{tp|p=21435128|t=2011. Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis.|pdf=|usr=}}{{21435128}}
{{tp|p=21421621|t=2011. Serum interleukin 6 levels and cirrhosis-associated pulmonary hypertension.|pdf=|usr=}}{{21421621}}
{{tp|p=21356197|t=2011. Involvement of STAT3-regulated hepatic soluble factors in attenuation of stellate cell activity and liver fibrogenesis in mice.|pdf=|usr=}}{{21356197}}
{{tp|p=21228704|t=2011. Portal levels of latent transforming growth factor-beta are related to liver function in patients with liver cirrhosis.|pdf=|usr=}}{{21228704}}
{{tp|p=20832949|t=2011. Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could oral antibiotics raise blood counts?|pdf=|usr=}}{{20832949}}
{{tp|p=20731703|t=2011. Peritoneal macrophage priming in cirrhosis is related to ERK phosphorylation and IL-6 secretion.|pdf=|usr=}}{{20731703}}
{{tp|p=20637651|t=2011. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis.|pdf=|usr=}}{{20637651}}
{{tp|p=20456041|t=2010. Admission levels and early changes in serum interleukin-10 are predictive of poor outcome in acute liver failure and decompensated cirrhosis.|pdf=|usr=}}{{20456041}}
{{tp|p=20193684|t=2010. Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis.|pdf=|usr=}}{{20193684}}
{{tp|p=19760951|t=2009. Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma.|pdf=|usr=}}{{19760951}}
{{tp|p=18562979|t=2009. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy.|pdf=|usr=}}{{18562979}}
{{tp|p=18455423|t=2008. IL-6 Promotes compensatory liver regeneration in cirrhotic rat after partial hepatectomy.|pdf=|usr=}}{{18455423}}
{{tp|p=17591083|t=2007. Interleukin-6 sustains hepatic regeneration in cirrhotic rat.|pdf=|usr=}}{{17591083}}
{{tp|p=17537833|t=2007. Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.|pdf=|usr=}}{{17537833}}
{{tp|p=17442294|t=2007. Vitamin B12 and hepatic enzyme serum levels correlate with interleukin-6 in alcohol-dependent individuals without liver disease.|pdf=|usr=}}{{17442294}}
{{tp|p=16698422|t=2006. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection.|pdf=|usr=}}{{16698422}}
{{tp|p=16629651|t=2006. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways.|pdf=|usr=}}{{16629651}}
{{tp|p=16617007|t=2006. Chronic bile duct obstruction induces changes in plasma and hepatic levels of cytokines and nitric oxide in the rat.|pdf=|usr=}}{{16617007}}
{{tp|p=16496306|t=2006. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair.|pdf=|usr=}}{{16496306}}
{{tp|p=15532800|t=2004. Interleukin-6 augments hepatocyte growth factor-induced liver regeneration; involvement of STAT3 activation.|pdf=|usr=}}{{15532800}}
{{tp|p=15482340|t=2004. Implication of inflammation-related cytokines in the natural history of liver cirrhosis.|pdf=|usr=}}{{15482340}}
{{tp|p=12830005|t=2003. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases.|pdf=|usr=}}{{12830005}}
{{tp|p=10755697|t=2000. Does IL-6 regulate liver fibrosis/cirrhosis directly and indirectly?|pdf=|usr=}}{{10755697}}
{{tp|p=11059648|t=2000. Serum levels of cytokines in alcoholic liver cirrhosis and pancreatitis.|pdf=|usr=}}{{11059648}}
{{tp|p=10928624|t=2000. Serum interleukin-6 and interferon-gamma levels in patients with hepatitis B-associated chronic liver disease.|pdf=|usr=}}{{10928624}}
{{tp|p=10520881|t=1999. Soluble interleukin-6 receptor levels in liver cirrhosis.|pdf=|usr=}}{{10520881}}
{{tp|p=10377517|t=1999. IL-6 and gp130 signalling: its role in chronic disease.|pdf=|usr=}}{{10377517}}
{{tp|p=10102225|t=1999. Thrombopoietic cytokines and reversal of thrombocytopenia after liver transplantation.|pdf=|usr=}}{{10102225}}
{{tp|p=9934750|t=1999. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis.|pdf=|usr=}}{{9934750}}
{{tp|p=9858790|t=1998. Changes in serum thrombopoietin levels after splenectomy.|pdf=|usr=}}{{9858790}}
{{tp|p=9166969|t=1997. Increased serum concentration of IgA2 subclass and IgA2/IgA1 ratio: specific markers of chronic alcoholic abuse?|pdf=|usr=}}{{9166969}}
{{tp|p=9155709|t=1997. Cytokines and the hepatic acute phase response.|pdf=|usr=}}{{9155709}}
{{tp|p=8734349|t=1996. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation.|pdf=|usr=}}{{8734349}}
{{tp|p=8531597|t=1995. High interleukin-6 production within the peritoneal cavity in decompensated cirrhosis and malignancy-related ascites.|pdf=|usr=}}{{8531597}}
{{tp|p=7540697|t=1995. Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction.|pdf=|usr=}}{{7540697}}
{{tp|p=7532385|t=1995. Antioxidative roles of metallothionein and manganese superoxide dismutase induced by tumor necrosis factor-alpha and interleukin-6.|pdf=|usr=}}{{7532385}}
{{tp|p=7930484|t=1994. Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis.|pdf=|usr=}}{{7930484}}
{{tp|p=7528963|t=1994. Cytokines and the liver in health and disease. Effects on liver metabolism and fibrogenesis.|pdf=|usr=}}{{7528963}}
{{tp|p=8281862|t=1994. High interleukin-6 concentrations in hepatic ascites.|pdf=|usr=}}{{8281862}}
{{tp|p=7511536|t=1993. Spontaneous bacterial peritonitis is associated with high levels of interleukin-6 and its secondary mediators in ascitic fluid.|pdf=|usr=}}{{7511536}}
{{tp|p=7980730|t=1993. High levels of tumor necrosis factor-alpha and interleukin-6 in the ascitic fluid of cirrhotic patients with spontaneous bacterial peritonitis.|pdf=|usr=}}{{7980730}}
{{tp|p=8482461|t=1993. Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients.|pdf=|usr=}}{{8482461}}
{{tp|p=8352843|t=1993. Tumour necrosis factor, interleukin-1 and interleukin-6 in alcoholic cirrhosis.|pdf=|usr=}}{{8352843}}
{{tp|p=8440420|t=1993. Interleukin 6 production by peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection and primary biliary cirrhosis.|pdf=|usr=}}{{8440420}}
{{tp|p=1612333|t=1992. Serum levels of cytokines in chronic liver diseases.|pdf=|usr=}}{{1612333}}
{{tp|p=1447505|t=1992. Interleukin-6 production by peripheral blood monocytes in patients with chronic liver disease and acute viral hepatitis.|pdf=|usr=}}{{1447505}}
{{tp|p=1736391|t=1992. Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery.|pdf=|usr=}}{{1736391}}
{{tp|p=1962626|t=1991. Serum interleukin 6 levels in patients with chronic hepatitis B.|pdf=|usr=}}{{1962626}}
{{tp|p=1753710|t=1991. Characterization of fat-storing cell lines derived from normal and CCl4-cirrhotic livers. Differences in the production of interleukin-6.|pdf=|usr=}}{{1753710}}
{{tp|p=1995437|t=1991. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients.|pdf=|usr=}}{{1995437}}
{{tp|p=1772964|t=1991. Genes for interleukin-1, interleukin-6, and tumor necrosis factor are expressed at markedly reduced levels in the livers of patients with severe liver disease.|pdf=|usr=}}{{1772964}}
{{tp|p=2184115|t=1990. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis.|pdf=|usr=}}{{2184115}}


 '''further aspects'''

{{tp|p=28167322|t=2017. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.|pdf=|usr=}}{{28167322}}
{{tp|p=28061755|t=2017. High serum resistin associates with intrahepatic inflammation and necrosis: an index of disease severity for patients with chronic HBV infection.|pdf=|usr=}}{{28061755}}
{{tp|p=27277679|t=2016. DJ-1 deficiency attenuates expansion of liver progenitor cells through modulating the inflammatory and fibrogenic niches.|pdf=|usr=}}{{27277679}}
{{tp|p=27226903|t=2016. Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation.|pdf=|usr=}}{{27226903}}
{{tp|p=27035642|t=2016. Inhibition of the translocation and extracellular release of high-mobility group box 1 alleviates liver damage in fibrotic mice in response to D-galactosamine/lipopolysaccharide challenge.|pdf=|usr=}}{{27035642}}
{{tp|p=26728971|t=2016. A deleterious role for Th9/IL-9 in hepatic fibrogenesis.|pdf=|usr=}}{{26728971}}
{{tp|p=26718412|t=2016. Coenzyme Q10 prevents hepatic fibrosis, inflammation, and oxidative stress in a male rat model of poor maternal nutrition and accelerated postnatal growth.|pdf=|usr=}}{{26718412}}
{{tp|p=26155043|t=2015. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.|pdf=|usr=}}{{26155043}}
{{tp|p=25886887|t=2015. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.|pdf=|usr=}}{{25886887}}
{{tp|p=25747515|t=2016. Synergic chemoprevention with dietary carbohydrate restriction and supplementation of AMPK-activating phytochemicals: the role of SIRT1.|pdf=|usr=}}{{25747515}}
{{tp|p=25663772|t=2015. Interleukin-22 ameliorates liver fibrogenesis by attenuating hepatic stellate cell activation and downregulating the levels of inflammatory cytokines.|pdf=|usr=}}{{25663772}}
{{tp|p=25171482|t=2014. Oxymatrine improves intestinal epithelial barrier function involving NF-kappaB-mediated signaling pathway in CCl4-induced cirrhotic rats.|pdf=|usr=}}{{25171482}}
{{tp|p=24841946|t=2014. Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells.|pdf=|usr=}}{{24841946}}
{{tp|p=24686514|t=2014. Signal transduction of platelet-induced liver regeneration and decrease of liver fibrosis.|pdf=|usr=}}{{24686514}}
{{tp|p=24616573|t=2014. Impaired balance of T helper 17/T regulatory cells in carbon tetrachloride-induced liver fibrosis in mice.|pdf=|usr=}}{{24616573}}
{{tp|p=24616207|t=2014. Macrophages and fibrosis in adipose tissue are linked to liver damage and metabolic risk in obese children.|pdf=|usr=}}{{24616207}}
{{tp|p=24383550|t=2014. The effect of antifibrotic drug halofugine on Th17 cells in concanavalin A-induced liver fibrosis.|pdf=|usr=}}{{24383550}}
{{tp|p=24260182|t=2013. The heme oxygenase system rescues hepatic deterioration in the condition of obesity co-morbid with type-2 diabetes.|pdf=|usr=}}{{24260182}}
{{tp|p=24225281|t=2014. Lipopolysaccharide binding protein in cirrhotic patients with severe sepsis.|pdf=|usr=}}{{24225281}}
{{tp|p=23840855|t=2013. Schistosomajaponicum Eggs Induce a Proinflammatory, Anti-Fibrogenic Phenotype in Hepatic Stellate Cells.|pdf=|usr=}}{{23840855}}
{{tp|p=23531302|t=2013. Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice.|pdf=|usr=}}{{23531302}}
{{tp|p=23299899|t=2013. Reticulon 4B (Nogo-B) facilitates hepatocyte proliferation and liver regeneration in mice.|pdf=|usr=}}{{23299899}}
{{tp|p=22916250|t=2012. Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha downregulation in experimental liver cirrhosis.|pdf=|usr=}}{{22916250}}
{{tp|p=22890552|t=2012. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture.|pdf=|usr=}}{{22890552}}
{{tp|p=22120983|t=2012. Toll-like receptor 4-dependent Kupffer cell activation and liver injury in a novel mouse model of parenteral nutrition and intestinal injury.|pdf=|usr=}}{{22120983}}
{{tp|p=22117531|t=2012. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease.|pdf=|usr=}}{{22117531}}
{{tp|p=21562239|t=2011. Suppression of amphiregulin/epidermal growth factor receptor signals contributes to the protective effects of quercetin in cirrhotic rats.|pdf=|usr=}}{{21562239}}
{{tp|p=21314960|t=2011. Induction of heme oxygenase-1 protects against nutritional fibrosing steatohepatitis in mice.|pdf=|usr=}}{{21314960}}
{{tp|p=21284667|t=2011. Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines.|pdf=|usr=}}{{21284667}}
{{tp|p=19676135|t=2009. Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6.|pdf=|usr=}}{{19676135}}
{{tp|p=19161105|t=2008. Changes in adrenal steroidogenesis in spontaneous bacterial peritonitis and sterile ascites.|pdf=|usr=}}{{19161105}}
{{tp|p=19065675|t=2009. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis.|pdf=|usr=}}{{19065675}}
{{tp|p=18794850|t=2008. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice.|pdf=|usr=}}{{18794850}}
{{tp|p=18571789|t=2008. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.|pdf=|usr=}}{{18571789}}
{{tp|p=18202114|t=2008. IL-6 downregulates transcription of NTPDase2 via specific promoter elements.|pdf=|usr=}}{{18202114}}
{{tp|p=16844679|t=2006. Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model.|pdf=|usr=}}{{16844679}}
{{tp|p=15194060|t=2004. Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats.|pdf=|usr=}}{{15194060}}
{{tp|p=12594232|t=2003. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis.|pdf=|usr=}}{{12594232}}
{{tp|p=28251449|t=2017. A20 Attenuates Liver Fibrosis in NAFLD and Inhibits Inflammation Responses.|pdf=|usr=}}{{28251449}}
{{tp|p=26957302|t=2017. Associations Between Hepatic Functions and Plasma Amyloid-Beta Levels-Implications for the Capacity of Liver in Peripheral Amyloid-Beta Clearance.|pdf=|usr=}}{{26957302}}
{{tp|p=26278387|t=2017. Review: Precision Cut Liver Slices for the Evaluation of Fatty Liver and Fibrosis.|pdf=|usr=}}{{26278387}}
{{tp|p=25908229|t=2015. Neurologic Manifestations of Chronic Liver Disease and Liver Cirrhosis.|pdf=|usr=}}{{25908229}}
{{tp|p=25416630|t=2015. Depletion of Foxp3+ Regulatory T Cells Promotes Profibrogenic Milieu of Cholestasis-Induced Liver Injury.|pdf=|usr=}}{{25416630}}
{{tp|p=24620819|t=2015. Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury.|pdf=|usr=}}{{24620819}}
{{tp|p=24239319|t=2014. Protective effects of L-carnitine, N-acetylcysteine and genistein in an experimental model of liver fibrosis.|pdf=|usr=}}{{24239319}}
{{tp|p=23998651|t=2014. Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.|pdf=|usr=}}{{23998651}}
{{tp|p=23948302|t=2013. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.|pdf=|usr=}}{{23948302}}
{{tp|p=23855303|t=2013. Interaction of hepatic stellate cells with diverse types of immune cells: foe or friend?|pdf=|usr=}}{{23855303}}
{{tp|p=23871639|t=2013. The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies.|pdf=|usr=}}{{23871639}}
{{tp|p=23842754|t=2013. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation.|pdf=|usr=}}{{23842754}}
{{tp|p=23728792|t=2013. Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death.|pdf=|usr=}}{{23728792}}
{{tp|p=23511062|t=2013. Effect of endotoxin on heart rate dynamics in rats with cirrhosis.|pdf=|usr=}}{{23511062}}
{{tp|p=23425082|t=2013. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.|pdf=|usr=}}{{23425082}}
{{tp|p=23350952|t=2013. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis?|pdf=|usr=}}{{23350952}}
{{tp|p=22683883|t=2012. Protective effects of curcumin against hepatic fibrosis induced by carbon tetrachloride: modulation of high-mobility group box 1, Toll-like receptor 4 and 2 expression.|pdf=|usr=}}{{22683883}}
{{tp|p=22185916|t=2012. Magnesium chenoursodeoxycholic acid ameliorates carbon tetrachloride-induced liver fibrosis in rats.|pdf=|usr=}}{{22185916}}
{{tp|p=22098272|t=2012. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia.|pdf=|usr=}}{{22098272}}
{{tp|p=22068968|t=2012. Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice.|pdf=|usr=}}{{22068968}}
{{tp|p=21822824|t=2011. Chronic inflammation and hepatocellular carcinoma.|pdf=|usr=}}{{21822824}}
{{tp|p=21742296|t=2011. Liver fibrogenesis and metabolic factors.|pdf=|usr=}}{{21742296}}
{{tp|p=21275501|t=2011. Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis.|pdf=|usr=}}{{21275501}}
{{tp|p=20969493|t=2011. Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice.|pdf=|usr=}}{{20969493}}
{{tp|p=20931291|t=2011. A natural process of cirrhosis resolution and deceleration of liver regeneration after thioacetamide withdrawal in a rat model.|pdf=|usr=}}{{20931291}}
{{tp|p=20399524|t=2010. Harmful effect of adipose tissue on liver lesions in patients with alcoholic liver disease.|pdf=|usr=}}{{20399524}}
{{tp|p=19857658|t=2009. Intestine as source of cytokines and growth factors.|pdf=|usr=}}{{19857658}}
{{tp|p=19642894|t=2009. Interleukin-6 trans-signaling regulates glycogen consumption after D-galactosamine-induced liver damage.|pdf=|usr=}}{{19642894}}
{{tp|p=19502117|t=2010. Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage.|pdf=|usr=}}{{19502117}}
{{tp|p=19413671|t=2009. Inhibition of hepatic tumour necrosis factor-alpha attenuates the anandamide-induced vasoconstrictive response in cirrhotic rat livers.|pdf=|usr=}}{{19413671}}
{{tp|p=19220679|t=2009. Pentoxifylline prevents pig serum-induced rat liver fibrosis by inhibiting interleukin-6 production.|pdf=|usr=}}{{19220679}}
{{tp|p=19118554|t=2009. B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis.|pdf=|usr=}}{{19118554}}
{{tp|p=18627003|t=2008. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease.|pdf=|usr=}}{{18627003}}
{{tp|p=18600481|t=2009. Inflammatory pathways in liver homeostasis and liver injury.|pdf=|usr=}}{{18600481}}
{{tp|p=18395094|t=2008. Nuclear factor-eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury.|pdf=|usr=}}{{18395094}}
{{tp|p=17998145|t=2008. Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin.|pdf=|usr=}}{{17998145}}
{{tp|p=17906854|t=2008. Hyperreninemic hypoaldosteronism syndrome, plasma concentrations of interleukin-6 and outcome in critically ill patients with liver cirrhosis.|pdf=|usr=}}{{17906854}}
{{tp|p=17512085|t=2007. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences.|pdf=|usr=}}{{17512085}}
{{tp|p=17222322|t=2007. An inverse relationship between markers of fibrogenesis and collagen degradation in patients with or without alcoholic liver disease.|pdf=|usr=}}{{17222322}}
{{tp|p=16941689|t=2006. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation.|pdf=|usr=}}{{16941689}}
{{tp|p=15990591|t=2005. Nonalcoholic fatty liver disease and the metabolic syndrome.|pdf=|usr=}}{{15990591}}
{{tp|p=15664244|t=2005. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis.|pdf=|usr=}}{{15664244}}
{{tp|p=15074396|t=2004. Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease.|pdf=|usr=}}{{15074396}}
{{tp|p=12640528|t=2003. Interleukin 6 concentration in ascitic fluid of cirrhotic patients: relationship with previous episodes of spontaneous bacterial peritonitis.|pdf=|usr=}}{{12640528}}
{{tp|p=12189115|t=2002. Small bowel bacterial overgrowth and endotoxemia in cirrhosis.|pdf=|usr=}}{{12189115}}
{{tp|p=12115021|t=2002. Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases.|pdf=|usr=}}{{12115021}}
{{tp|p=10755691|t=2000. Induction of hepatic stellate cell proliferation by LPS-stimulated peripheral blood mononuclear cells from patients with liver cirrhosis.|pdf=|usr=}}{{10755691}}
{{tp|p=10535885|t=1999. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential.|pdf=|usr=}}{{10535885}}
{{tp|p=10493891|t=1999. Fibrosin: A novel lymphokine in alcohol-induced fibrosis.|pdf=|usr=}}{{10493891}}
{{tp|p=10395040|t=1999. Inhibition of concanavalin A-induced acute T cell dependent hepatic damage in mice by hypothyroidism.|pdf=|usr=}}{{10395040}}
{{tp|p=9888410|t=1999. Treatment with glutathione precursor decreases cytokine activity.|pdf=|usr=}}{{9888410}}
{{tp|p=9622456|t=1998. Altered T-lymphocyte responsiveness to polyclonal cell activators is responsible for liver cell necrosis in alcohol-fed rats.|pdf=|usr=}}{{9622456}}
{{tp|p=9581682|t=1998. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor.|pdf=|usr=}}{{9581682}}
{{tp|p=7533191|t=1995. Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo.|pdf=|usr=}}{{7533191}}
{{tp|p=8589343|t=1995. Roles of oxidative stress in activation of Kupffer and Ito cells in liver fibrogenesis.|pdf=|usr=}}{{8589343}}
{{tp|p=1639344|t=1992. Immunomodulatory effects of ursodeoxycholic acid on immune responses.|pdf=|usr=}}{{1639344}}